Different conformational responses of the β(2)-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline

β(2)-肾上腺素能受体-Gs复合物与部分激动剂沙丁胺醇或完全激动剂异丙肾上腺素结合后,其构象反应不同。

阅读:1

Abstract

G protein-coupled receptors (GPCRs) are responsible for most cytoplasmic signaling in response to extracellular ligands with different efficacy profiles. Various spectroscopic techniques have identified that agonists exhibiting varying efficacies can selectively stabilize a specific conformation of the receptor. However, the structural basis for activation of the GPCR-G protein complex by ligands with different efficacies is incompletely understood. To better understand the structural basis underlying the mechanisms by which ligands with varying efficacies differentially regulate the conformations of receptors and G proteins, we determined the structures of β(2)AR-Gα(s)[Formula: see text]γ bound with partial agonist salbutamol or bound with full agonist isoprenaline using single-particle cryo-electron microscopy at resolutions of 3.26 Å and 3.80 Å, respectively. Structural comparisons between the β(2)AR-Gs-salbutamol and β(2)AR-Gs-isoprenaline complexes demonstrated that the decreased binding affinity and efficacy of salbutamol compared with those of isoprenaline might be attributed to weakened hydrogen bonding interactions, attenuated hydrophobic interactions in the orthosteric binding pocket and different conformational changes in the rotamer toggle switch in TM6. Moreover, the observed stronger interactions between the intracellular loop 2 or 3 (ICL2 or ICL3) of β(2)AR and Gα(s) with binding of salbutamol versus isoprenaline might decrease phosphorylation in the salbutamol-activated β(2)AR-Gs complex. From the observed structural differences between these complexes of β(2)AR, a mechanism of β(2)AR activation by partial and full agonists is proposed to provide structural insights into β(2)AR desensitization.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。